Skip to main
OCUL

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix is a biotechnology company with a promising pipeline of eye medication using its proprietary hydrogel platform technology. Though the company currently only has one revenue-generating product, the potential for future commercial success is high. However, there are financial risks due to the need for substantial funding, as well as regulatory and commercial risks that may hinder the approval and commercialization of its pipeline candidates. Despite some manageable safety concerns, the company's patent portfolio may face challenges and potential infringement claims from competitors or third parties.

Bears say

Ocular Therapeutix is a high-risk investment that heavily relies on the success of their pipeline candidate, Axpaxli. However, there are risks involved in terms of clinical trial results, regulatory approvals, and market competition, which could potentially impact the stock's volatility. Additionally, the company heavily relies on securing additional funding and partnerships to advance their pipeline and achieve commercial success. Despite a successful Phase 3 trial, the stock saw a dramatic decline due to lower-than-expected results, providing a potential buying opportunity for investors.

Ocular Therapeutix (OCUL) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Ocular Therapeutix (OCUL) has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.